Home » Stocks » AMTI

Applied Molecular Transport, Inc. (AMTI)

Stock Price: $34.19 USD -0.78 (-2.23%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $36.00 +1.81 (5.29%) Jul 23, 4:47 PM
Market Cap 1.31B
Revenue (ttm) n/a
Net Income (ttm) -71.72M
Shares Out 38.28M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $34.19
Previous Close $34.97
Change ($) -0.78
Change (%) -2.23%
Day's Open 35.00
Day's Range 32.15 - 35.40
Day's Volume 138,057
52-Week Range 20.50 - 78.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology

2 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D....

2 months ago - GlobeNewsWire

Enrollment ongoing in each of oral AMT-101's four Phase 2 trials

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its prev...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an under...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced a...

3 months ago - GlobeNewsWire

Company continues to strengthen key functions of corporate leadership

4 months ago - GlobeNewsWire

Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing

4 months ago - GlobeNewsWire

Here's why these highfliers could have more fuel in the tank.

Other stocks mentioned: GRTS, MRNA
4 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph....

4 months ago - GlobeNewsWire

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects

4 months ago - GlobeNewsWire

About AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I... [Read more...]

Industry
Biotechnology
IPO Date
Jun 5, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AMTI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AMTI stock is "Strong Buy." The 12-month stock price forecast is 75.75, which is an increase of 121.56% from the latest price.

Price Target
$75.75
(121.56% upside)
Analyst Consensus: Strong Buy